Latest Paclitaxel Stories
SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr.
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy INDIANAPOLIS, Nov.
Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov.
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
HARBIN, China, Oct. 30, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc.
Trial will test the potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer ST. HELIER, Jersey, Oct.
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 5, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S.
CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).